Phase 2 Study of Oral K201 for Prevention of AF Recurrence
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 300 participants.
Also called NCT01067833
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 300 participants
- Sponsor
- Sequel Pharmaceuticals, Inc
- Registry
-
NCT01067833
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01067833. Randomized; quadruple masking; primary purpose prevention. Start 2010-04 (registry gives no type); primary completion 2011-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Study of Oral K201 for Prevention of AF Recurrence
- Acronym
- ARCTIC-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- K201 Tablet
- Intervention (Drug)
- Placebo Tablet
- Lead sponsor
- Sequel Pharmaceuticals, Inc
Record details
- Record id
cardio:ct-nct01067833- Content hash
c59228a0e61e46d51878c4685dfa2a7e4279f09d006a5454919bd8de52bc4bca